Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220997 | 0.85 | KDM4E (0.35) | — | |
| SCHEMBL2220435 | 0.85 | KDM4E (0.35) | — | |
| SCHEMBL2219155 | 0.84 | PTAFR (0.48) | PTAFR | |
| SCHEMBL7927257 | 0.81 | GRM2 (0.32) | — | |
| SCHEMBL7915024 | 0.81 | GRM2 (0.32) | — | |
| SCHEMBL1512020 | 0.79 | CYP2D6 (0.36) | PTAFRCYP2D6DPP4 | |
| SCHEMBL12441129 | 0.78 | GRM2 (0.35) | — | |
| SCHEMBL1511845 | 0.70 | LMNA (0.42) | PTAFRCYP2D6 | |
| SCHEMBL7922204 | 0.69 | GRM2 (0.46) | — | |
| SCHEMBL8007560 | 0.68 | SMN1; SMN2 (0.34) | CYP2D6DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2010036544-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178117-A1 | OXAZOLOBENZIMIDAZOLE DERIVATIVES | GRM2, GRM1, GRM3 | PTAFR 1620/4885CYP2D6 2440/4885DPP4 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.